Phase 2 Efficacy Study of Primaquine and Methylene Blue

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Malaria
Interventions
DRUG

Sulphadoxine-pyrimethamine

Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.

DRUG

0.25 mg/kg primaquine

Primaquine will be administered in an aqueous solution according to weight-based dosing.

DRUG

Dihydroartemisinin-piperaquine

160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.

DRUG

Methylene blue

Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.

DRUG

Amodiaquine

Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.

Trial Locations (1)

Unknown

Malaria Research and Training Centre, Bamako

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

London School of Hygiene and Tropical Medicine

OTHER

collaborator

Heidelberg University

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

University of California, San Francisco

OTHER

NCT02831023 - Phase 2 Efficacy Study of Primaquine and Methylene Blue | Biotech Hunter | Biotech Hunter